The efficacy and safety of treatments for acute gout: results from a series of systematic literature reviews including Cochrane reviews on intraarticular glucocorticoids, colchicine, nonsteroidal antiinflammatory drugs, and interleukin-1 inhibitors [0.03%]
急性期痛风治疗疗效和安全性的系列系统综述的成果：包括糖皮质激素、秋水仙碱、非甾体抗炎药及白介素-1抑制剂等的多项考科蓝系统评价
Mihir D Wechalekar,Ophir Vinik,John H Y Moi et al.
Mihir D Wechalekar et al.
Objective: To determine the efficacy and safety of glucocorticoids (GC), colchicine, nonsteroidal antiinflammatory drugs (NSAID), interleukin-1 (IL-1) inhibitors, and paracetamol to treat acute gout. ...
Cardiovascular risk factors and comorbidities in patients with hyperuricemia and/or gout: a systematic review of the literature [0.03%]
高尿酸血症和/或痛风患者的危险因素和共病：文献系统回顾
Caroline van Durme,Irene A A M van Echteld,Louise Falzon et al.
Caroline van Durme et al.
Objective: To review the available literature on the likelihood of having cardiovascular (CV) risk factors and on developing CV comorbidities in patients with gout and/or asymptomatic hyperuricemia as an evidence base for...
Diagnostic value of clinical, laboratory, and imaging findings in patients with a clinical suspicion of gout: a systematic literature review [0.03%]
临床怀疑痛风患者临床、实验室和影像学检查诊断价值的系统文献回顾
Francisca Sivera,Mariano Andrès,Louise Falzon et al.
Francisca Sivera et al.
Objective: To analyze the diagnostic utility of clinical, laboratory, and imaging items for gout. Methods: A systematic literature sear...
Introduction: diagnosis and management of gout. Systematic literature reviews of the 3e Initiative 2011-2012 [0.03%]
痛风的诊断和治疗：3E行动2011-2012系统文献回顾之简介
Désirée van der Heijde,Rachelle Buchbinder
Désirée van der Heijde
Cost for tuberculosis care in developed countries: which data for an economic evaluation? [0.03%]
发达国家抗结核治疗费用：经济评估所需的数据有哪些？
Leopoldo Trieste,Giuseppe Turchetti
Leopoldo Trieste
Tuberculosis (TB) seems to be eradicated in developed countries. However, current migration flows and increasing use of immunosuppressive and biologic drugs for rheumatic diseases are increasing the risk of latent TB and TB onset for citize...
Restarting biologics and management of patients with flares of inflammatory rheumatic disorders or psoriasis during active tuberculosis treatment [0.03%]
生物制剂的重启及活动性结核病患者炎症风湿性疾病或银屑病发作的管理
Fabrizio Cantini,Francesca Prignano,Delia Goletti
Fabrizio Cantini
Our aim was to review the evidence concerning optimal timing for restarting biologics in patients with active tuberculosis (TB), and the management of relapsing rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (A...
Marialuisa Bocchino,Alessandro Matarese,Alessandro Sanduzzi
Marialuisa Bocchino
Treatment of latent tuberculosis infection (LTBI) is a key component in TB control strategies worldwide. However, as people with LTBI are neither symptomatic nor contagious, any screening decision should be weighed carefully against the pot...
Leonardo Pescitelli,Federica Ricceri,Francesca Prignano
Leonardo Pescitelli
The treatment of some dermatological diseases, especially psoriasis, has been revolutionized by the advent of biologic therapies that target various immune cells or cytokines. However, biologic therapies may affect the risk of active tuberc...
Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries [0.03%]
非肿瘤坏死因子α(TNF-α)靶向生物制剂和最近上市的TNF-α抑制剂治疗患者的肺结核发病风险：临床试验与国家登记资料的数据分析
Fabrizio Cantini,Laura Niccoli,Delia Goletti
Fabrizio Cantini
This review aimed to evaluate the risk of active tuberculosis (TB) occurrence in patients with rheumatic disorders receiving non-anti-tumor necrosis factor (TNF) targeted biologics anakinra (ANK), tocilizumab (TCZ), rituximab (RTX), abatace...
Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance [0.03%]
阿达木单抗、英夫利昔和依那西普与结核病风险：临床试验、国家登记数据及药物警戒系统的证据
Fabrizio Cantini,Laura Niccoli,Delia Goletti
Fabrizio Cantini
This review evaluates the risk of tuberculosis (TB), adherence with recommendations for TB prevention, and host-related risk in patients with rheumatoid arthritis (RA), psoriatic arthritis, and ankylosing spondylitis receiving infliximab (I...